MedTrace Logo

Endocan Levels at Polycystic Ovary Syndrome and Periodontal Inflammation

NCT03264846 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 87

Last updated 2020-02-10

No results posted yet for this study

Summary

Periodontal diseases are chronic inflammatory disease occurred by the interaction between pathogenic microorganism and the host defense. Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disease associated with increased risk of cardiovascular events. Endocan is a proteoglycan secreted mainly by endothelial cells under the control of inflammatory cytokines.

Periodontal diseases, including gingivitis, are common chronic infectious diseases caused by predominantly pathogenic microorganisms that colonize the subgingival area and cause local and systemic elevations of proinflammatory cytokines such as Interleukin-6 (IL-6).

Several lines of evidence established the association between periodontal and systemic diseases, including metabolic syndrome, diabetes, and cardiovascular disease.

Because of the fact that both periodontal disease and PCOS are associated with systemic inflammation and insulin resistance, these two disorders may be linked through a common pathophysiologic pathway.

A number of studies have indicated a possible relationship between PCOS and periodontal inflammation. Despite common risk factors, including oxidative stress, the relationship between chronic periodontitis (CP) and PCOS remains unclear.

The aims of the study were to determine serum and saliva Endocan and IL-6 levels and to evaluate the correlation between these two biomarker in women with periodontal disease and PCOS.

Conditions

  • Polycystic Ovary Syndrome
  • Inflammation Gum
  • Cytokines

Interventions

DIAGNOSTIC_TEST

Collection of Serum and Saliva Samples

Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.

Sponsors & Collaborators

  • Ataturk University

    collaborator OTHER

  • Ebru Saglam

    lead OTHER

Principal Investigators

  • Ebru Sağlam, PhD · Bezmialem Vakif University

  • Ayşe Toraman · Ataturk University

  • Engin Şebin · Erzurum Regional Training and Research Hospital

  • Cenk Fatih Çanakçı, Professor · Ataturk University

  • Hümeyra Çanakçı, Dr · Private Practice

  • Metin İngeç, Professor · Ataturk University

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-03
Primary Completion
2017-11-29
Completion
2017-11-29

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03264846 on ClinicalTrials.gov